CDH1 , CAV1 , NR3C1 , and ZEB1 are Potential Biomarkers in Colorectal Cancer Drug Resistance and Prognosis
Technology in Cancer Research & Treatment · 2026-03 · 25
DOI: 10.1177/15330338261430993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 10.03.2026. Verfasst von Pengfei Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Soochow University, Suzhou City, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Biomarkers, Tumor, Zinc Finger E-box-Binding Homeobox 1, Colorectal Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with drug resistance and poor prognosis significantly limiting treatment efficacy. To address this unmet clinical need, this study aimed to screen potential biomarkers for CRC drug resistance and prognosis through integrated bioinformatics analysis and clinical sample validation.
Methods
We analyzed Gene Expression Omnibus (GEO) database GSE153412 to screen differentially expressed genes (DEGs) between 5-fluorouracil (5-FU)-resistant and sensitive CRC cells (|log2FC| > 1.0, adj P < 0.05). Gene set enrichment analysis (GSEA) was used for pathway enrichment, Weighted gene co-expression network analysis (WGCNA) to identify resistance-related modules (correlation > 0.7, P < 0.01), and Protein-protein interaction (PPI) networks to screen hub genes. Their prognostic value was evaluated in TCGA-COAD, along with IC50 correlation. Finally, qPCR verified biomarker expression in clinical CRC samples.
Results
There were altogether 1033 DEGs screened. Through GSEA, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) terms enriched by the DEGs were obtained. By PPI network construction, hub genes were screened. In TCGA-COAD datasets, CAV1 (P = 0.018) , CDH1 (P = 0.049) , CXCL8 (P = 0.00068) , CD24 (P = 0.00017) , NR3C1 (P = 0.016) , and ZEB1 (P = 0.042) were also related to CRC prognosis. The correlation analysis of key genes and drug resistance suggested the emergence of CDH1 , CAV1 , NR3C1 , and ZEB1 , which was also examined by clinical data validation.
Conclusion
Integrated bioinformatics and clinical validation analyses identified CDH1 , CAV1 , NR3C1 , and ZEB1 as key biomarkers for CRC. These genes were significantly associated with 5-FU resistance and CRC prognosis, as supported by their dysregulated expression in clinical samples, highlighting their mechanistic roles in the CRC drug resistance pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Soochow University, Suzhou City, China.
- Department of General Surgery, The People's Hospital of Rugao, Rugao Hospital Affiliated to Nantong University, Rugao City, China.
- Department of General Surgery, Suqian First Hospital, Suqian City, China.
ORCID-Profile: Yongyou Wu
Zitieren
APA
Wu, P., Liu, G., Shao, L., & Wu, Y. (2026). CDH1 , CAV1 , NR3C1 , and ZEB1 are Potential Biomarkers in Colorectal Cancer Drug Resistance and Prognosis. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261430993
Vancouver
Wu P, Liu G, Shao L, Wu Y. CDH1 , CAV1 , NR3C1 , and ZEB1 are Potential Biomarkers in Colorectal Cancer Drug Resistance and Prognosis. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261430993
BibTeX
@article{Wu2026,
author = {Wu, Pengfei and Liu, Guodong and Shao, Lening and Wu, Yongyou},
title = {CDH1 , CAV1 , NR3C1 , and ZEB1 are Potential Biomarkers in Colorectal Cancer Drug Resistance and Prognosis},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261430993}
}
EUVIMED